DUBLIN, Mar. 14, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/zv5f56/china_heparin) has announced the addition of the "Concise Analysis of the Chinese Heparin Industry" report to their offering.
Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe's total) and heparin APIs are gradually recognized internationally, China has grown into the largest heparin API producing and exporting country around the globe.
Nevertheless, due to the stagnant demand in European and American markets in recent two years and the improved standards for heparin export, the export volume and value of heparin APIs in China both presented a decline trend during 2011-2012. In 2012, the export volume of heparin APIs in China only registered 103.86 tons (with a year-on-year decline of 1.3%), or about 14.5 trillion units (based on 140IU/mg), addressing 46.5% of global heparin API demand in corresponding period.
Although leading heparin enterprises have had the plans of capacity expansion and heparin industrial chain improvement in previous years, affected by sluggish market demand, enhanced technical standards and other factors, a number of heparin API projects originally planned to start production in 2012 or 2013 were postponed successively, such as the 5T/A project of Hepalink, 2.8T/A project of Dongcheng Bio-chemicals, 4T/A unfractionated heparin sodium and 1.2T/A low-molecular-weight heparin sodium project of Nanjing King-friend. The API project of Qianhong Bio-pharma was completed at the end of 2012, but has not been put into production yet.
Key Topics Covered:
1. Overview of Heparin Industry
2. Operating Environment of Heparin Industry in China
3. Development of Heparin API Industry in China
4. Development of Heparin Preparation Industry in China
5. Key Heparin Enterprises in China
- Changshan Biochemical
- Dongcheng Biochemicals
- Jiangsu Wanbang
- Qianhong Bio-pharma
- Tianjin Chase Sun
- Wanbang Biochemical
For more information visit http://www.researchandmarkets.com/research/zv5f56/china_heparin
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets